AF
RCUS icon

Amalgamated Financial’s Arcus Biosciences RCUS Stock Holding History

Amalgamated Financial’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$171K Buy
+5,409
New +$181K ﹤0.01% 1955

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Amalgamated Financial's RCUS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Arcus Biosciences (RCUS) in Q1 2022: 5,409 shares worth $171K. The stake represents ﹤0.01% of the portfolio and ranks #1955 among its holdings.

157 funds tracked by Wall St. Rank hold RCUS as of Q1 2022.

  • Amalgamated Financial held 5,409 shares of Arcus Biosciences worth $171K as of Q1 2022.
  • Arcus Biosciences was a new Amalgamated Financial position in Q1 2022.
  • Arcus Biosciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1955 holding.
  • 157 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.